VNTA (Ventana Biotech) may be one of the most compelling stories that I have ever heard in the small cap arena.
I believe that VNTA could be about to explode in value. Please take the time to do your homework on VNTA. I do not see VNTA staying at this price for long!
The following is what a very savvy and shrewd Wall Street investor had to say on VNTA this morning:
VENTANA BIOTECH: (VNTA) $.55 Up $.05.... Here''s a speculative penny biotech that could really heat up. A huge promotion will begin any day now. Promoters brought the stock down from $2.25 on Tuesday to gear up for the promotion. Could it trade back to $2.25? Maybe so - particularly based on the story behind the company. Ventana Biotech reminds me of a similar company MDO recommended back in 2000 by the name of QUIGLEY CORP. (QGLY). Quigley Corp is the maker of Cold-Eeze, a zinc based cold tablet that either stops a common cold from beginning or shortens its length. The company was in the very initial stages of starting to market its proprietary zinc gluconate glycine lozenge for treating the common cold. The stock was under a buck and it made a run to $17.00. Today, Cold-Eeze is in every major drug store across the nation, including Wal-mart, chain food stores as well as mass merchandise stores and pharmacies.
Could Ventana Biotech be just as successful as Quigley Corp.? Here''s the story.....
Ventana''s main focus is the development of an appetite suppressing chewing gum. The idea behind the product will emulate the body''s natural signals for feeling full using a drug based on a natural gut hormone produced after every meal. It is likely to be developed as an injectable drug first but the company''s main focus is for consumers to be able to take the product in the form of a chewing gum.
Ventana is not looking at a toxic drug, which has all sorts of side effects. Rather, the company is looking at the body''s own way of switching off its appetite after a meal. In the western world, more than a 20% of adults are obese and of the remaining population half of men and a third of women are classified as overweight and early indications prove that the company''s drug is able to reduce a person''s appetite by 15% to 25%.
Drugs to tackle obesity often have unpleasant side effects, Ventana’s aim is to create a drug that will be free of side effects because it already circulates in the body. The body produces the hormone after every meal to ensure eating does not run out of control. There is evidence that some people have more of the hormone than others, and becoming overweight reduces the levels produced.
If Ventana Biotech could turn out to be just half as successful as Quigley Corp., we''ll have a huge success story.
Could Ventana Biotech be just as successful as Quigley Corp.? Here''s the story.....
Ventana''s main focus is the development of an appetite suppressing chewing gum. The idea behind the product will emulate the body''s natural signals for feeling full using a drug based on a natural gut hormone produced after every meal. It is likely to be developed as an injectable drug first but the company''s main focus is for consumers to be able to take the product in the form of a chewing gum.
Ventana is not looking at a toxic drug, which has all sorts of side effects. Rather, the company is looking at the body''s own way of switching off its appetite after a meal. In the western world, more than a 20% of adults are obese and of the remaining population half of men and a third of women are classified as overweight and early indications prove that the company''s drug is able to reduce a person''s appetite by 15% to 25%.
Drugs to tackle obesity often have unpleasant side effects, Ventana’s aim is to create a drug that will be free of side effects because it already circulates in the body. The body produces the hormone after every meal to ensure eating does not run out of control. There is evidence that some people have more of the hormone than others, and becoming overweight reduces the levels produced.
If Ventana Biotech could turn out to be just half as successful as Quigley Corp., we''ll have a huge success story.
No comments:
Post a Comment